Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Lonza completes bioconjugation facility expansion

1
SHARES

The planned expansion of Lonza’s bioconjugation facility in Visp, Switzerland has been completed, the company has announced.

Lonza completes bioconjugation facility expansion

Credit: Taljat David / Shutterstock.com

Lonza, a contract development and manufacturing organisation (CDMO), has announced that the planned expansion of its bioconjugation facility in Visp, Switzerland is complete.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The expansion includes two manufacturing suites which will support companies entering clinical development. The investment will help support both clinical and commercial supply and be a key part in helping the company to meet the growing market demand for bioconjugates. 

Lonza’s new manufacturing suites

The new suites add to Lonza’s recent investments in its Visp site, in microbial development, drug product development and manufacturing, and highly potent active pharmaceutical ingredient (HPAPI) payload-linker manufacturing capacity. A benefit is that customers of all sizes will have access to solutions in a single location. The company stated the facilities are designed to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, to support future growth, the expansion also includes an increase in process and analytical development and quality control capacity.

Stefan Egli, Vice President, Head of Bioconjugates at Lonza commented on the opening of the bioconjugate facility’s new manufacturing suites in Visp: “Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programmes.”

Other Lonza manufacturing expansions 

Lonza announced an investment to further expand bioconjugation capabilities at its Visp site in December 2020. The expansion was planned to add two production suites. In addition, an extension to laboratory space was anticipated to double the analytical and process development capacity, according to Lonza. The new capabilities were expected to be fully operational in 2022.

In September 2022, Lonza opened the expansion of its HPAPI multipurpose manufacturing suite in Visp. The company stated that the suite included enhanced capability for antibody-drug conjugate (ADC) payload production.

Share via
Share via